DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application. (2017). SKIN The Journal of Cutaneous Medicine, 1(3.1), s46. https://doi.org/10.25251/skin.1.supp.45